DRTS
What one share of Alpha Tau Medical holds
Surgical and Medical Instruments and Apparatus
We are a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Our proprietary Alpha DaRT® technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation’s limited range.
Alpha Tau Medical’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$0.53 |
|---|---|
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | −$0.41 |
| Cash and investments | $0.14 |
| Book value | $0.88 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$0.25 | $0.04 | −$0.24 | — | −$0.01 |
| 2020 | — | −$0.22 | $0.09 | −$0.27 | — | −$0.21 |
| 2021 | — | −$0.67 | $0.07 | −$0.36 | — | −$0.86 |
| 2022 | — | −$0.53 | $0.01 | −$0.39 | — | $1.53 |
| 2023 | — | −$0.42 | $0.09 | −$0.35 | — | $1.21 |
| 2024 | — | −$0.45 | $0.03 | −$0.31 | — | $0.89 |
| 2025 | — | −$0.53 | $0.08 | −$0.41 | — | $0.88 |